Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Declines By 12.8%

Aileron Therapeutics, Inc. (NASDAQ:ALRN) was the recipient of a large decrease in short interest during the month of July. As of July 31st, there was short interest totalling 270,800 shares, a decrease of 12.8% from the July 15th total of 310,600 shares. Based on an average daily trading volume, of 64,100 shares, the short-interest ratio is presently 4.2 days. Currently, 1.5% of the shares of the stock are short sold.

Analyst Ratings Changes

Separately, Brookline Capital Management upgraded shares of Aileron Therapeutics to a “strong-buy” rating in a research report on Thursday, May 30th.

Aileron Therapeutics Stock Up 14.5 %

Shares of NASDAQ:ALRN opened at $1.89 on Monday. Aileron Therapeutics has a 52 week low of $1.01 and a 52 week high of $7.42. The firm has a 50 day moving average of $2.70 and a 200 day moving average of $4.03. The company has a market capitalization of $40.85 million, a price-to-earnings ratio of -0.59 and a beta of 2.23.

Aileron Therapeutics (NASDAQ:ALRN) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.20). On average, sell-side analysts expect that Aileron Therapeutics will post -1.36 EPS for the current year.

Insider Transactions at Aileron Therapeutics

In other Aileron Therapeutics news, major shareholder Of Texas/Texas Am I. University sold 9,577 shares of the stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $3.30, for a total value of $31,604.10. Following the completion of the sale, the insider now owns 1,768,250 shares in the company, valued at approximately $5,835,225. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, major shareholder Of Texas/Texas Am I. University sold 9,577 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $3.30, for a total transaction of $31,604.10. Following the completion of the sale, the insider now owns 1,768,250 shares of the company’s stock, valued at $5,835,225. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Of Texas/Texas Am I. University sold 9,342 shares of the stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $3.25, for a total transaction of $30,361.50. Following the transaction, the insider now owns 1,753,156 shares in the company, valued at approximately $5,697,757. The disclosure for this sale can be found here. Insiders have sold 33,557 shares of company stock valued at $109,966 in the last quarter. Insiders own 5.57% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Warberg Asset Management LLC purchased a new position in Aileron Therapeutics during the second quarter worth about $86,000. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Aileron Therapeutics in the second quarter worth $4,925,000. Texas Capital Bank Wealth Management Services Inc boosted its holdings in Aileron Therapeutics by 65.9% in the first quarter. Texas Capital Bank Wealth Management Services Inc now owns 26,171 shares of the company’s stock valued at $174,000 after purchasing an additional 10,398 shares during the period. Finally, Sigma Planning Corp purchased a new stake in Aileron Therapeutics during the 4th quarter worth about $51,000. Institutional investors and hedge funds own 90.89% of the company’s stock.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).